European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Unde...(s nearly 1.5 million people in the Unite...)

Date:2/23/2009

s nearly 1.5 million people in the United States annually.(2) Heart attack is a major manifestation of coronary heart disease, which occurs when the arteries become narrowed or clogged by cholesterol and fat deposits. In some cases the plaque can rupture, resulting in a blood clot, which may partially or totally block the blood supply to portions of the heart, resulting in ACS.(3) Many ACS patients undergo PCI to re-open the artery, which usually includes a stent placement.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit www.dsus.com.

(1) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008, http://www.ehnheart.org/files/statistics%202008%20web-161229A.pdf, Accessed December 9, 2008.

(2) American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. htt
'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
2. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
3. Registration Open for OpenClinica European Summit - April 14, 2009
4. Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project
5. Myngle Best ICT Company at the European Ventures Summit
6. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
7. Kuvan Receives Marketing Approval in the European Union
8. BioLife Solutions Granted European Biopreservation Patent
9. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
10. Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System
11. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market